|
MechanismPhosphatidylinositol 3-kinase family inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
100 Clinical Results associated with Suzhou Junde Biotechnology Company, Ltd.
0 Patents (Medical) associated with Suzhou Junde Biotechnology Company, Ltd.
100 Deals associated with Suzhou Junde Biotechnology Company, Ltd.
100 Translational Medicine associated with Suzhou Junde Biotechnology Company, Ltd.